Long-acting reversible contraception (LARC) with the intrauterine system with levonorgestrel (6 mcg/d): observational study on the acceptability, quality of life, and sexuality in Italian women

References

• World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization ; 2015.
   Google Scholar
• Hall KS , Castaño PM , Westhoff CL. The influence of oral contraceptive knowledge on oral contraceptive continuation among young women. J Womens Health (Larchmt) 2014;23:596–601.
   PubMed Web of Science ®Google Scholar
• Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab 2013;11:41–7.
   PubMedGoogle Scholar
• Caruso S , Iraci M , Cianci S , et al . Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis associated pelvic pain on 2 mg dienogest/30 μg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest 2016;39:923–31.
   PubMed Web of Science ®Google Scholar
• Caruso S , Agnello C , Intelisano G , et al . Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2005;72:19–23.
   PubMed Web of Science ®Google Scholar
• Caruso S , Malandrino C , Cicero C , et al . Quality of sexual life of women on oral contraceptive continued-regimen: pilot study. J Sex Med 2013;10:460–6.
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ , Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577–82.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F , Perini D , Fornaciari L , et al . Discontinuation of modern hormonal contraceptives: an Italian survey. Eur J Contracept Reprod Health Care 2016;21:449–54.
   PubMed Web of Science ®Google Scholar
• Chiofalo B , Laganà AS , Imbesi G , et al . Is oral contraceptive-induced headache dependent on patent foramen ovale? Clinical dynamics, evidence-based hypothesis and possible patient-oriented management. Med Hypotheses 2016;94:86–8.
   PubMed Web of Science ®Google Scholar
• Kulkarni J , Liew J , Garland KA . Depression associated with combined oral contraceptives-a pilot study. Aust Fam Physician 2005;34:990.
   PubMedGoogle Scholar
• Coleman PK. Abortion and mental health: quantitative synthesis and analysis of research published 1995–2009. Br J Psychiatry 2011;199:180–6.
   PubMed Web of Science ®Google Scholar
• Gipson JD , Koenig MA , Hindin MJ. The effects of unintended pregnancy on infant, child, and parental health: a review of the literature. Stud Fam Plann 2008;39:18–38.
   PubMed Web of Science ®Google Scholar
• Ortiz ME , Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007;75:S16–S30.
   PubMed Web of Science ®Google Scholar
• Ortiz ME , Croxatto HB , Bardin CW. Mechanisms of action of intrauterine devices. Obstet Gynecol Surv 1996;51:S42–S51.
   PubMedGoogle Scholar
• Apter D , Gemzell-Danielsson K , Hauck B , et al . Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril 2014;101:1656–62.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K , Schellschmidt I , Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 2012;97:616–22.
   PubMed Web of Science ®Google Scholar
• Fan G , Kang S , Ren M , et al . A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population. Contraception 2017;95:371–7.
   PubMed Web of Science ®Google Scholar
• Suvisaari J , Lähteenmäki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996;54:201–8.
   PubMed Web of Science ®Google Scholar
• Bayer HealthCare Pharmaceuticals Inc . Mirena® (levonorgestrel-releasing intrauterine system). Summary of product characteristics. 2009. Available at: External link http://www.berlex.com/html/products/pi/Mirena_PI.pdf [last accessed 2 Aug 2011].
   Google Scholar
• Nelson AL , Apter D , Hauck B , et al . Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol 2013;122:1205–13.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K , Buhling KJ , Dermout SM , et al . A phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg) in postmenarcheal adolescents. Contraception 2016;93:507–12.
   PubMed Web of Science ®Google Scholar
• Cristobal I , Neyro J-L , Lete I. The new LNG-releasing IUS: a new opportunity to reduce the burden of unintended pregnancy. Eur J Obstet Gynecol Reprod Biol 2015;190:58–64.
   PubMed Web of Science ®Google Scholar
• The American College of Obstetricians and Gynaecologists women’s health care physicians . Practice Bulletin. Clinical Management Guidelines for obstetrician–gynecologists Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 2011;118:184–96.
   PubMedGoogle Scholar
• Apolone G , Mosconi P. The Italian SF-36 Health Survey: translation, validation and norming. J Clin Epidemiol 1998;51:1025–36.
   PubMed Web of Science ®Google Scholar
• Rosen R , Brown C , Heiman J , et al . The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208.
   Google Scholar
• Apter D , Briggs P , Tuppurainen M , et al . A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertil Steril 2016;106:151–7.
   PubMed Web of Science ®Google Scholar
• Greco T , Graham CA , Bancroft J , et al . The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 μg of ethinyl estradiol. Contraception 2007;76:8–17.
   PubMed Web of Science ®Google Scholar
• Poromaa IS , Segebladh B. Adverse mood symptoms with oral contraceptives. Acta Obstet Gynecol Scand 2012;91:420–7.
   PubMed Web of Science ®Google Scholar
• Caruso S , Agnello C , Intelisano G , et al . Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene. Contraception 2004;69:237–40.
   PubMed Web of Science ®Google Scholar
• De Sanctis V , Soliman A , Bernasconi S , et al . Primary dysmenorrhea in adolescents: prevalence, impact and recent knowledge. Pediatr Endocrinol Rev 2015;13:512–20.
   PubMed Web of Science ®Google Scholar
• Neri M , Malune ME , Corda V , et al . Body composition and psychological improvement in healthy premenopausal women assuming the oral contraceptive containing micronized estradiol (E2) and nomegestrol acetate (NOMAC). Gynecol Endocrinol 2017;9:1–5.
   Google Scholar
• Fruzzetti F , Lello S , Lazzarini V , et al . The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 2007;75:199–203.
   PubMed Web of Science ®Google Scholar
• Uras R , Orrù M , Etzi R , et al . Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass. Contraception 2009;79:117–21.
   PubMed Web of Science ®Google Scholar